Educational new article on our new delivery tech | SRPT Message Board Posts


Sarepta Therapeutics Inc.

  SRPT website

SRPT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  14468 of 14491  at  8/17/2022 7:04:51 PM  by

schmiggins

The following message was updated on 8/17/2022 7:18:10 PM.

Educational new article on our new delivery tech

This very well-written article will help a lot of investors learn how to separate the wheat from the chaff as far as gene therapy companies go.

https://www.thestreet.com/investing/did-sarepta-therapeutics-just-unveil-a-breakthrough?puc=yahoo&cm_ven=YAHOO

One (misleading) point he makes really only applies to our current shortened DMD molecule...Our LGMD drugs use the original full-length gene. He seems to think all our gene therapy molecules are shortened versions. Not so.


"It's also important for investors to acknowledge one unaddressed drawback: MyoAAV delivery shuttles will still have a relatively low capacity. That will force Sarepta Therapeutics to continue using miniaturized versions of replacement genes instead of full-length, human copies. Higher delivery efficiency should reduce the impact of this limitation, but the drawback looms."


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...